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The enigmatic role of mast cells in dominant tolerance
Victor C. de Vries, Karina Pino-Lagos, Raul Elgueta, and Randolph J. Noelle
Department of Microbiology and Immunology, Dartmouth Medical School and Norris Cotton
Cancer Center, Lebanon, New Hampshire, USA
Abstract
Purpose of review—The role of regulatory T cells (Treg) in peripheral tolerance has been
studied extensively in transplantation research. Recently, mast cells have been shown to play an
indispensable role in allograft tolerance. The purpose of this review is to inform the reader on the
current standings of the role of mast cells in dominant tolerance with an emphasis on the
interaction of mast cells with Treg.
Recent findings—Mast cells are required to sustain peripheral tolerance via Treg. Treg can
stabilize mast cells degranulation by contact-dependent mechanisms through the interaction of
OX40 and its ligand OX40L, and by production of soluble factors, such as interleukin-10 and
transforming growth factor-β. Conversely, the activation and subsequent degranulation of mast
cells break peripheral tolerance.
Summary—Both mast cells and Treg are needed to create a local immunosuppressive
environment in the transplant. Treg are not only necessary to suppress effector T-cell responses but
also to stabilize mast cells. Mast cells in return could contribute to the immunosuppressive state by
release of transforming growth factor-β, interleukin-10 and specific proteases. However, the
molecular basis for mast cells control of Treg suppression in organ transplantation is still
unresolved.
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Introduction
Peripheral tolerance, subdivided in linked suppression and infectious tolerance, is explained
by the generation of regulatory T cells (Treg) in the periphery called adaptive Treg (aTreg)
[1]. The importance of aTreg in organ transplantation has been reported in clinical and
animal studies [2,3]. Additionally, mast cells are necessary in the establishment of peripheral
tolerance [4,5], and multiple studies [6,7,8••,9,10,11•,12] have addressed the impact of Treg
on the stabilization of mast cells by several mechanisms. Conversely, how mast cells
influence Treg or contribute to suppression of alloreactive immune responses needs yet to be
elucidated. On the basis of current knowledge of mast cells, we will discuss some of the
possible modes of interaction.
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Background
The establishment of an adaptive immune system is dependent on a complex series of events
to avoid self-reactivity. With regard to T-cell development, progenitors migrate from bone
marrow to the thymus in which rigorous selection steps take place known as ‘central
tolerance’. During this process, a small proportion of thymocytes upregulates the forkhead
transcription factor forkhead box P3 (FoxP3) [13–15]. These T cells, called natural Treg
(nTreg), have profound suppressive capacity in the development and function of effector T
cells (Teff) [16]. They are able to silence self-reactive Teff that have escaped thymics
election as shown in autoimmunity studies [17,18]. Furthermore, during antigen presentation
by dendritic cells in the absence of costimulation, nTreg are able to induce a suppressor
phenotype in naive T cells (called adaptive Treg, aTreg). This active process is known as
infectious tolerance.
In allogeneic organ transplantation, the introduction of foreign proteins leads to the rapid
expansion of Teff and subsequent rejection. Both experimental and clinical studies [2,3] have
shown the importance of Treg in organ transplantation. Many experimental approaches have
been designed to induce a population of Treg with specificity for these alloantigens to allow
the allogeneic tissue to be accepted. Indeed, when looking at cellular composition in
accepted grafts large numbers of Treg are present. Curiously, another cell type is also
abundantly present: the mast cell.
Mast cells are members of the innate immune system and can be found at locations that are
in close contact with the outside world such as skin, lung and intestinal mucosa. They are
characterized by staining of granules with basic dyes [19], such as toluidine blue, and can
also be detected by antibody staining for the highly expressed stem cell factor receptor, c-
kit, in combination with the high affinity immunoglobulin E (IgE) receptor, FcεRI [20].
Until recently, they have been considered proinflammatory in both protection against
parasitic infections and allergies. This side of the mast cells is based on the activation and
subsequent degranulation mediated by cross-linking of FcεRI by IgE [20,21]. The
immediate response leads to the release of a wide array of proinflammatory mediators,
chemotactic factors and proteolytic enzymes, inducing a rapid inflammation and tissue
remodeling [21]. Further, mast cells aid in wound healing by releasing factors that promote
fibrogenic activities, platelet activation and recruitment of leukocytes to fight off possible
infection [22–26]. Thus, although detrimental in allergies, the role of mast cells in mounting
an immune response to defend against parasites and in maintaining the physical barrier is
indispensable.
Mast cells are not known for their immune suppressive capacities, and many correlative
studies [27] show an increased number of mast cells in rejecting grafts, suggesting that mast
cells play a role in preventing graft tolerance. However, the initial work by Zelenika et al.
[28] showed a high expression of mast cells-related gene products in tolerant grafts,
emphasizing the beneficial role for mast cells in maintaining peripheral tolerance.
Additionally, our laboratory showed, in a skin graft model, the functional need for mast cells
during the initiation phase of tolerance [5]. This finding was later confirmed in a heterotopic
heart transplant model [4]. The duality of mast cells as positive and negative regulators of
the immune response is only beginning to be resolved.
Dominant tolerance
As mentioned above, tolerance can be defined depending on the mechanism involved in its
establishment. In this regard, recessive tolerance is accomplished by deletion of alloreactive
T cells. On the contrary, dominant tolerance is explained by the generation of aTreg and
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manifested as linked suppression and infectious tolerance, which will be discussed below
[1].
Regulatory T cells
Early observations suggested that a specific population of CD4+ T cells is responsible for
the prevention of autoimmune diseases. Elimination of these cells through genetic mutation
in the Foxp3 gene, in the mutant mouse strain scurfy [29] and the human X-linked recessive
syndrome immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) [30],
resulted in profound systemic autoimmunity. FoxP3 is expressed in regulatory CD25+CD4+
T cells, and retroviral transduction of FoxP3 in naive CD4+CD25− T cells engendered
suppressive properties among these cells [14]. In addition, transfer of this subset of CD4 T
cells was able to protect against the development of autoimmunity [31]. Therefore, FoxP3 is
regarded as a key marker that defines Treg.
It was shown that Treg suppresses the proliferation of the effector population by inhibition of
interleukin (IL)-2 secretion on the target cells. This can either be contact dependent by
activation of its T-cell receptor [32] through the expression of granzyme A [33] or B [34] or
in a contact-independent manner via IL-10 [35], IL-35 or transforming growth factor beta
(TGF-β) [36]. Further research demonstrated that more than one population of Treg can be
found, which can be divided in two main groups. As described above, nTreg and aTreg, the
latter including several distinct populations: regulatory type 1 T cell (Tr1) (IL-10-producing
T cells) [35], T helper cell type 3 (Th3) (TGF-β-producing T cells) [36] and a recently
described subset of reversion-resistant Treg derived in the presence of the vitamin A
metabolite retinoic acid [37].
Linked suppression and infectious tolerance
Davies et al. [38] showed that copresentation of tolerated self-antigen with nontolerated
alloantigen on the same antigen-presenting cell led to tolerance to both self-antigens, now
known as linked suppression. This process is independent of CD8+ T cells, showing that the
newly induced Treg are sufficient for this effect [39].
Another mechanism was revealed when naive T cells from untreated mice were transferred
into tolerated mice in which all T cells were deleted by thymectomy and CD4 antibody
treatment. These naive T cells were able to break the established tolerance [40].
Surprisingly, when the infused naive lymphocytes are allowed to coexist for 2 weeks with
the tolerated T-cell repertoire before deleting this endogenous pool of lymphocytes,
tolerance to skin grafts was maintained [41]. These elegant experiments clearly demonstrate
that naive T cells can become suppressive by the coexistence with tolerant cells and was
named ‘infectious tolerance’. Years later, the same observations were confirmed using a
cardiac allograft transplantation model [42].
The mast cells–regulatory T cell axis in dominant tolerance
Although the role of Treg in the maintenance of peripheral tolerance is quite established,
other cells of the immune system contribute significantly. As mentioned previously, mast
cells are known for their proinflammatory properties, and it was surprising that mast cells
were absolutely required for the establishment of tolerance toward an allogeneic transplant
[4,5]. Still unclear are the mechanisms of interaction between the Treg and the mast cells that
help maintain a favorable mast cell–Treg axis in dominant tolerance.
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Proinflammatory and immune suppressive mast cells
It is known that during the maintenance phase of dominant tolerance, mast cells have a
detrimental effect on graft survival, especially in highly vascularized tissues such as kidney,
heart and lung. This effect has been attributed to the slow non-IgE-mediated degranulation
causing fibrosis and intima hyperplasia [4,43,44]. In favor of this notion, a retrospective
study [45] among allergic rhinitis patients who received a kidney transplant showed more
severe episodes of rejection compared with non-atopic transplanted patients, suggesting that
the release of proinflammatory mediators caused by IgE-mediated degranulation of mast
cells induces the overt inflammation. We confirmed this finding in a skin graft model with
ovalbumin-sensitized mice. Subsequent local challenge led to acute rejection of the graft,
showing that mast cell degranulation breaks established acquired tolerance (unpublished
observation).
However, we and others [4,5] have shown that for the establishment of tolerance, mast cells
are essential. Further, in the murine skin graft model, increased levels of IL-9 were found.
IL-9 is a cytokine abundantly secreted by Treg and is known to enhance mast cells growth
and chemotaxis. The observation that IL-9 neutralization leads to graft loss confirms that
IL-9 is an important molecular link between Treg and mast cells [5].
Regulatory T cell dampens the proinflammatory properties of mast cells
Recently, it was reported that Treg can directly stabilize mast cells by desensitizing mast
cells against FcεRI-mediated degranulation. It has been shown in an in-vitro system with
bone marrow-cultured mast cells that Treg can downregulate FcεRI in a contact-dependent
manner [11•]. Additionally, Gri et al. [8••] showed that Treg can increase cyclic AMP
(cAMP) and inhibit intracellular calcium flux in mast cells degranulation by OX40–OX40
ligand (OX40L) interaction in vitro and in vivo. This mechanism of mast cells
desensitization was independent of IL-10 and TGF-β [11•].
However, IL-10, TGF-β and also IL-4 have been shown to have an impact on mast cells
development, survival and FcεRI expression by different mechanism [6,7,10,12,46]. It was
observed in signal transducer and activator of transcription 6 (STAT6)−/− mice that STAT6
signaling was absolutely required for IL-4-mediated FcεRI down-regulation [46], and the
synergistic effect of IL-10 was not impaired [6]. In the presence of IL-4, the expression of
the FcεRI-β-subunit was decreased, with minimal impact on the expression of the α-subunit,
and no effect was observed on the expression of the γ-subunit. This down-regulation of
FcεRI resulted in reduced responsiveness during late phase response characterized by
infiltration of leukocytes and measured by tumor necrosis factor alpha (TNF-α) release.
However, the immediate responses (that is, the release of granular content) were not altered,
as measured by β-hexoaminidase release [6]. In the case of IL-10, it was shown that FcεRI
downregulation was STAT3 dependent and also induced reduction of STAT5, Akt, Syk and
Fyn in mast cells [12]. The latter four molecules are part of different pathways known to be
involved in IgE-mediated degranulation [47–49]. However, the effect of IL-10 treatment had
a significant impact on the immediate response to IgE [12]. Lastly, TGF-β impacts the rate
of protein synthesis of the IgE receptor and not RNA expression, suggesting that TGF-β may
regulate mast cells functions via posttranslation mechanisms [7]. The effects of TGF-β on
protein synthesis have recently been shown to be SMAD dependent [50].
These observations clearly show that, during dominant tolerance, Treg not only play an
important role in suppressing effector T-cell development and function but are also needed
to regulate the responsiveness of mast cells to IgE. That Treg have a diminished suppressive
capacity in atopic patients [51–53] could, therefore, contribute to increased mast cells
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degranulation and thus aggravating allergic inflammation, whereas in graft tolerance, the
Treg suppress this proinflammatory response by suppressing FcεRI expression.
Possible contributions of mast cells to dominant tolerance
Although it is clear that Treg can directly influence mast cells function, little is known about
the effects of mast cells on Treg. Here, we discuss some of the possible mechanisms that
mast cells employ to regulate acquired peripheral tolerance.
Mast cells produce IL-10 and TGF-β, two suppressive cytokines. As such, mast cells are
able to suppress T-cell proliferation and could possibly generate aTreg via the production of
these cytokines. Indeed, mast cells can downregulate antigen-specific T-cell proliferation
after mosquito bites in an IL-10-mediated fashion, suggesting that IL-10 is one of the
immune suppressive mediators released by mast cells [54]. That IL-10 plays an important
role in suppressing immune responses was emphasized by a study [9] in contact dermatitis,
in which IL-10 derived from mast cells significantly reduced the skin disease as measured
by leukocyte infiltration and inflammation. Moreover, this group [9] and others [55,56]
showed in both rodents and humans that low levels of either ultraviolet A (UVA) or UVB
irradiation lead to activation of mast cells in the skin with the subsequent release of both
IL-10 and histamine. Additionally, type I interferons (IFNs) induce IL-10 and TGF-β
secretion by human mast cells; however, it also downregulates OX40L [57]. As has been
shown in the murine bladder carcinoma (MB49) model, tumors can induce IL-10 production
by the infiltrating leukocytes, thereby contributing to the immunosuppressive environment
[58]. Although the role of mast cells in tumors is not clear yet, their presence has been
linked to a bad prognosis. IL-10 derived from mast cells could contribute to the generation
of tumor-specific aTreg. Therefore, next to the Treg, it is likely that one of the main sources
of IL-10 during tumor development is the mast cell [59,60]. The possible positive effects of
immune suppression in transplantation have mostly been attributed to the presence of Treg,
whereas the negative effect of fibroses and intima hyperplasia mostly point at the mast cells
[43,61–64]. However, the actual impact of the mast cells-derived IL-10 and TGF-β on
dominant tolerance has yet to be established.
Mast cells express the serotonin-specific transporter (SERT) that enables them to take up
and store serotonin. When mast cells get activated by IgE, the stored serotonin can be
released. Serotonin is considered an accessory ‘third’ signal for T-cell proliferation and is
involved in early T-cell activation of both naive CD4+ and CD8− T cells [65–67]. It is,
therefore, plausible that under tolerant conditions mast cells actively deplete the local
environment of serotonin needed for robust T-cell responses.
Moreover, the ability to present antigen in the context of major histocompatibility complex
class II (MHC-II) could also imply that they are able to influence T-cells responses. More
recently, it has been shown that mast cells express other costimulatory molecules of both the
TNF superfamily [OX40L, CD30 ligand (CD30L), Fas and glucocorticoid-induced TNF
receptor (GITR)] as well as the B7 family [CD80, CD86, PD ligand 1 (PD-L1) and PD-L2],
making them bona fide antigen-presenting cells [68]. Recently, Nakano et al. [69••] showed
that Notch signaling was required for upregulation of both MHC-II and OX40L on mast
cells. However, these mast cells skewed naive T cells to a Th2 phenotype, inducing the
production of IL-4, IL-10 and IL-13 and suppressing the production of IFN-γ. It is known
that the environment in a graft is Th2 skewed [70], therefore suggesting that antigen
presentation by mast cells, under tolerant conditions, could benefit graft acceptance.
Lastly, the release of a wide array of de-novo-generated (proteolytic) enzymes could
modulate the direct cytokine environment. Although nothing is known about the role of mast
cell proteases in organ transplantation, we observed upregulation of monocyte
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chemoattractant protein 1 (MCP1) and MCP5 in tolerated allogeneic grafts [5]. Recently, the
study [71] of a patient who had received a kidney transplant also showed elevated levels of
mast cells tryptases in the blood, although no correlation was found with graft function.
A barrier with addressing the role of mast-cell-derived mediators in tolerance and immunity
is the ability to conditionally control the production of defined mediators by mast cells.
However, with the development of mast cells-specific protease driven Cre knock-in mice
[72•,73•], the technology to temporally, conditionally and spatially control mast cells
synthesis of mediators in vivo is now possible.
Conclusion
There is little doubt that mast cells are regulators of adaptive immune responses. Figure 1
shows the described interactions between mast cells and T cells in a very simplified form.
Many results come from observations without having defined the mediators that underlie the
phenomena. However, it is recognized that there is a complex set and series of interactions
between mast cells and Treg. The two faces of mast cells, either as inducers of inflammation
or regulators of tolerance, are likely based on whether mediators are released by
degranulation or secretion, the nature of the subsets of mast cells that are involved and other
environmental cues that control mast cells phenotype. Defining the molecular basis for mast
cells regulation of immunity and tolerance is the quest for the future.
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Figure 1. Interaction of mast cells with T cells under inflammatory and tolerant conditions
The binding of allergen IgE to the high affinity IgE receptor FcεRI arms the MC.
Subsequent encounter with the allergen leads to the immediate release of granular content
leading to a proinflammatory response as seen in allergies. This response leads to
suppression of Treg functionality and recruitment and proliferation of Teff among other
proinflammatory leukocytes. However, under tolerant condition, the MCs are needed to
establish an immunosuppressive environment. The Treg present in the graft not only
suppress Teff but also the proinflammatory properties of the MC mainly by influencing the
expression of the FcεRI. IL, interleukin; IgE, immunoglobulin E; MC, mast cell; OX40L,
OX40 ligand; Teff, effector T cell; Treg, regulatory T cell; TGF-β, transforming growth
factor beta. , regulatory T cell; , effector T cell; , mast cell.
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